NEW YORK (GenomeWeb) – Instruments manufacturer Intellicyt announced today that it is teaming up with oncology clinical lab Notable Labs to develop a predictive personalized medicine platform to help clinicians make treatment decisions for cancer patients.
Notable Labs will integrate Intellicyt's iQue Screener Plus platform into a fully automated, high-throughput lab to immune-profile phenotypic and functional endpoints of cells and secreted proteins through cell- and bead-based assays. Treatment options in order of priority will then be sent to clinicians.
The iQue Screener platform is an integrated instrument, software, and reagent system using a flow cytometry-based detection system to enable the rapid assessment of cells and beads in suspension in 96-, 384-, and 1,536-well plates, the company said. The data is then analyzed using the firm's ForeCyt software. Notable Labs' approach is to help oncologists make treatment decisions by testing therapies on a patient's own cells.
"The iQue Screener Plus offers deeper insights into which treatments target cancer cells while sparing a patient's healthy cells," said Notable Labs CEO Matt De Silva in a statement. "High-throughput flow cytometry provides us with new capabilities to observe real-time drug sensitivity for individual patients on a single cell level."
Financial terms of the deal were not disclosed.
In June 2015, Intellicyt signed a collaboration deal with Genedata to work on cell-based screening in drug discovery. The firms integrated Genedata's Screener software with the iQue Screener system.